Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation

• Published in: Chinese medical journal Vol. 136; no. 7; pp. 848 - 850
• Main Authors: Mao, Shiqi, Luo, Libo, Yang, Shuo, Wang, Yan, Zhou, Fei, Yu, Jia, Chen, Bin, Gao, Guanghui, Li, Xuefei, Zhao, Chao, Cheng, Lei, Liu, Yiwei, Wang, Wanying, Jia, Keyi, Shao, Chuchu, Liu, Xinyu, Chen, Xiaoxia, Su, Chunxia, Zhou, Caicun, Wu, Fengying, Ren, Shengxiang
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins Ovid Technologies 05.04.2023; Lippincott Williams & Wilkins; Wolters Kluwer
• Subjects: Aminoquinolines - therapeutic use; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Chemotherapy; Correspondence; Hospitals; Humans; Immunotherapy; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Medical prognosis; Mutation; Mutation - genetics; Patients; Standard of Care; United States > US; China
• ISSN: 2542-5641; 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000002453

[...]patients were dichotomized into pyrotinib and SoC groups. In the current study, we firstly compared the efficacy of pyrotinib with SoC, and found that pyrotinib was significantly associated with an improved ORR, prolonged PFS, and numerically prolonged OS. Since the simultaneous or sequential use of ICIs and osimertinib has resulted in significantly increased grade 3/4 side effects, we also assessed the efficacy and side effects of the sequential use of ICIs and pyrotinib. [...]a relatively small number of patients, especially only five patients who received the sequential use of ICIs and pyrotinib, were enrolled in the final analysis. [...]antibody-drug conjugates such as T-DM1 and DS-8201a are unavailable in China, thus the findings of this study cannot be generalized to the global population.